The U.S. Federal Trade Commission has cleared AbbVie to acquire Allergan, and the High Court of Ireland has approved the transaction.
“The acceptance by the FTC satisfies all required antitrust clearances needed to be obtained,” according to a press release from AbbVie.
Brent Saunders, Allergan chairman and CEO, will not join the AbbVie board as was initially planned in order “to pursue other opportunities in the sector,” the release said.
Allergan’s eye care portfolio includes Durysta (bimatoprost implant 10 µg), Lumigan (bimatoprost ophthalmic solution 0.01%),
Uncategorized